• RedHill Biopharma won a Nasdaq extension to regain compliance with the $1.00 minimum bid price rule.
• New deadline set for April 5, 2027, following an initial compliance period that ended Oct. 5, 2026.
• Nasdaq will close the matter if the ADS bid price holds at or above $1.00 for 10 consecutive business days.
• Notice does not immediately affect the ADS listing or trading on Nasdaq Capital Market under RDHL.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Redhill Biopharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-004732), on October 07, 2026, and is solely responsible for the information contained therein.